6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine
C22H27FN8 — CID 121391056
Data last refreshed: (MolForge compound catalog, from PubChem)
About 6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine
6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (PubChem CID 121391056) has the molecular formula C22H27FN8 and a molecular weight of 422.51 g/mol. Its IUPAC name is 6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine.
Molecular Properties
| Compound Name | 6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine |
|---|---|
| PubChem CID | 121391056 |
| Molecular Formula | C22H27FN8 |
| Molecular Weight | 422.51 g/mol |
| Exact Mass | 422.23 |
| IUPAC Name | 6-[1-[2-(3-fluoroazetidin-1-yl)ethyl]pyrazol-4-yl]-4-(1-pentan-3-ylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine |
| SMILES | CCC(CC)n1cc(-c2nc(-c3cnn(CCN4CC(F)C4)c3)cn3nccc23)cn1 |
| InChI | InChI=1S/C22H27FN8/c1-3-19(4-2)30-12-17(10-26-30)22-21-5-6-24-31(21)15-20(27-22)16-9-25-29(11-16)8-7-28-13-18(23)14-28/h5-6,9-12,15,18-19H,3-4,7-8,13-14H2,1-2H3 |
| InChIKey | ZFVDBFPIDVFUKU-UHFFFAOYSA-N |
| XLogP | 3.47 |
| TPSA | 69.07 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 422.51 |
| LogP ≤ 5 | 3.47 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 121391056 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.